IP Library Granted Patent US 46,617
Granted Patent E1
US 46,617 · App. 14/743,365 · Granted Nov 28, 2017

Process for making quinolone compounds

Inventors: Roger Hanselmann (Branford, CT); Maxwell M. Reeve (Guilford, CT); Graham Johnson (Madison, CT)
Assignee: MELINTA THERAPEUTICS, INC.
C07D401/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 46,617
App. No.
14/743,365
Granted
Nov 28, 2017
Kind
E1
Abstract

The present invention relates to the field of synthesizing anti-infective compounds. More particularly, the invention relates to synthesizing a family of quinolone compounds useful as anti-infective agents. The invention includes a process for preparing a quinolone compound wherein less than about 0.40% of dimeric impurity of the quinolone is produced.

Claims (22)

1. A process for preparing a quinolone compound comprising the step of reacting a des-chloro quinolone compound or a pharmaceutically acceptable salt or ester thereof with a chlorinating agent and an acid, wherein the molar ratio of the acid to des-chloro quinolone is from about 0.007 0.008 to about 0.02 0.012, and wherein less than about 0.40% 0.35% of dimeric impurity on an area percent basis of the quinolone is produced, wherein the quinolone compound is 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt or ester thereof and the des-chloro quinolone compound is 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-hydroxy-azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt or ester thereof, and wherein the dimeric impurity is 1-amino-3-(azetidin-3-yloxy)-propan-2-ol-bis(N,N′-quinolone carboxylic acid), or a pharmaceutically acceptable salt or ester thereof.

2. A process according to claim 1 wherein the quinolone compound is 1-(6-Amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt or ester thereof and the des-chloro quinolone compound is 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-hydroxy-azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt or ester thereof.

3. A process according to claim 2 wherein the dimeric impurity is 1-Amino-3-(azetidin-3-yloxy)-propan-2-ol-bis (N,N′-quinolone carboxylic acid), or a pharmaceutically acceptable salt or ester thereof.

4. A process according to claim 1 wherein the chlorinating agent is N-chlorosuccinimide.

5. A process according to claim 1 wherein the acid is selected from the group consisting of sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, trifluoroacetic acid, triflic acid, methanesulfonic acid, p-toluene-sulfonic acid, or perchloric acid, and mixtures thereof.

6. A process according to claim 1 wherein the acid is sulfuric acid.

7. A process according to claim 1 where the reaction is run at a temperature from about 0° C. to about 30° C.

8. A process according to claim 1 wherein the molar ratio of N-chlorosuccinimide the chlorinating agent to des-chloro quinolone is greater than about 1.

9. A process according to claim 1 using an acetate ester as a solvent.

10. A process according to claim 9 wherein said acetate ester is selected from the group consisting of methyl acetate, ethyl acetate, and mixtures thereof.

11. A process according to claim 9 wherein said acetate ester is methyl acetate.

12. A process according to claim 1 comprising the further step of reacting the quinolone compound with a base.

13. A process according to claim 12 wherein the base is a hydroxide base.

14. A process according to claim 13 wherein the hydroxide base is selected from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, barium hydroxide, and mixtures thereof.

15. A process according to claim 14 wherein the hydroxide base is potassium hydroxide.

16. A process according to claim 12 using a mixture of isopropanol and water as a solvent.

17. A process according to claim 1 wherein said process is a commercial scale process.

18. A composition comprising the quinolone compound 1-(6-Amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt or ester thereof having less than about 0.40% 0.35% of the compound 1-Amino-3-(azetidin-3-yloxy)-propan-2-ol-bis(N,N′-quinolone 1-amino-3-(azetidin-3-yloxy)-propan-2-ol-bis(N,N′-quinolone carboxylic acid), or a pharmaceutically acceptable salt or ester thereof on an area percent basis of the quinolone.

19. A composition according to claim 18 wherein said composition is a commercial scale composition.

20. The process of claim 1 or 2 , wherein the molar ratio of chlorinating agent to des-chloro quinolone is from about 1.05 to about 1.2.

21. The process of claim 1 or 2 , wherein the molar ratio of chlorinating agent to des-chloro quinolone is from about 1.04 to about 1.07.

22. The process of claim 1 or 2 , wherein the molar ratio of acid to des-chloro quinolone is from about 0.008 to about 0.012.

Assignments (9)
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (PATENTS) AT REEL 054836 AND FRAME 0824, REEL 061314 AND FRAME 0572 AND REEL 068260 AND FRAME 0283 Recorded Aug 29, 2025
From: SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 074576/0471 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2022
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 061314/0572 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 22, 2020
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 054836/0824 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →
RELEASE OF SECURITY INTEREST Recorded Jan 5, 2018
From: SUCHARD SA LLC
To: MELINTA SUBSIDIARY CORP. (F/K/A MELINTA THERAPEUTICS, INC.)
Reel/Frame 044547/0939 →
CHANGE OF NAME Recorded Dec 19, 2017
From: MELINTA THERAPEUTICS, INC.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 044437/0647 →
SECURITY INTEREST Recorded Jun 28, 2017
From: MELINTA THERAPEUTICS, INC.
To: SUCHARD SA LLC
Reel/Frame 042854/0753 →
CHANGE OF NAME Recorded Dec 20, 2016
From: RIB-X PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 041033/0167 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2016
From: HANSELMANN, ROGER; REEVE, MAXWELL M.; JOHNSON, GRAHAM
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 040594/0839 →
Continuity (2)
Reissue 13120278 · Sep 23, 2009
Provisional Application 61194083 · Sep 24, 2008